Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 18/20 | 1.00 |
| ▸ | VEGFA | P15692 | 6/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21004976 | 1.00 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL16555510 | 0.87 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL16560812 | 0.87 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL18036746 | 0.87 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL18036745 | 0.87 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL21572965 | 0.84 | EPAS1 (0.76) | EPAS1VEGFA | |
| SCHEMBL16560993 | 0.83 | VEGFA (1.00) | EPAS1VEGFA | |
| SCHEMBL18036730 | 0.83 | VEGFA (1.00) | EPAS1VEGFA | |
| SCHEMBL18036738 | 0.80 | VEGFA (1.00) | EPAS1VEGFA | |
| SCHEMBL16555912 | 0.80 | VEGFA (1.00) | EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49948-E1 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| CN-110372550-B | Aryl ethers and their use | 佩洛通治疗公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20210222257-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-22 | — | — | US | disclosed |
| US-20210015764-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA | PELOTON THERAPEUTICS INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3417851-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10597366-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597366-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | PELOTON THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20170217891-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217891-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217891-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217892-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217892-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217892-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | MGMT, NEFM, TUBB3 | EPAS1 2505/4885VEGFA 189/4885 |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | EPAS1 16/4885VEGFA 45/4885 |
| US-20210222257-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | HIF1AN, HIF1A, EGLN2 | EPAS1 14/4885VEGFA 641/4885 |
| US-20210015764-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA | HIF1AN, EGLN2, EGLN3 | EPAS1 30/4885VEGFA 2429/4885 |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885VEGFA 21/4885 |
| US-20170217892-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885VEGFA 21/4885 |
| US-20170217891-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885VEGFA 21/4885 |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885VEGFA 21/4885 |
| US-10597366-B2 | Aryl ethers and uses thereof | HIF1AN, EGLN2, VHL | EPAS1 9/4885VEGFA 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.